Dare Bioscience Investor Presentation Deck

Daré - Working to Accelerate Innovation in Women's Health Program Milestones remaining in 2022 include a product launch, data readout, and Phase 3 investigator meeting*: XACIATO (clindamycin phosphate) vaginal gel, 2% (f/k/a DARE-BV1) Commercial launch in the U.S. in 4Q 2022 ● Ovaprene® (hormone-free monthly contraception) Pivotal Phase 3 study investigator meeting 12/2022; recruitment initiation mid-2023* DARE-VVA1 (vaginal atrophy treatment for women with breast cancer) Phase 1/2 study topline data during 4Q-2022 Sildenafil Cream, 3.6% (female sexual arousal disorder) Phase 2b study enrollment expected to complete 4Q-2022 . *Currently anticipated timing 15

View entire presentation